A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function

Trial Profile

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Delayed graft function
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT study
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 03 Feb 2017 This trial has been completed in Czech Republic (end date: 22 Nov 2016).
    • 31 Jan 2017 This trial has been completed in France (End date:2016-11-22) according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top